Press Releases

InVivo Therapeutics Announces Northwestern Medicine as New Site for INSPIRE Study

Published: August 18, 2016

CAMBRIDGE, Mass. (Aug 18, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Northwestern Medicine in Chicago, IL has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Surgeries will be performed at the Northwestern Memorial Hospital, an 894-bed Level I trauma center. “Chicago, as with other major metropolitan areas, sees a disproportionally high number of acute, traumatic spinal cord injuries and unfortunately, with complete spinal cord injuries, trauma teams have limited tools at […]

View Article
InVivo Therapeutics Announces Fifth Patient Conversion in INSPIRE Study of the Neuro-Spinal Scaffold™

Published: August 17, 2016

Conversion Rate to Date is Four Times the Rate in Natural History Databases CAMBRIDGE, Mass. (Aug 17, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the ninth patient implanted with the Neuro-Spinal Scaffold™ in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between the two and three-month evaluations. This is the fifth out of the eight patients (62.5% conversion rate) in followup to have had an AIS grade improvement to date. Several large natural history databases indicate that fewer than 16% of patients with complete thoracic injuries […]

View Article
InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer

Published: August 11, 2016

CAMBRIDGE, Mass. (Aug 11, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Pamela Stahl to the newly-created position of Chief Commercial Officer (CCO), effective September 14, 2016. In this role, she will be responsible for building a comprehensive global commercial strategy that includes developing the company’s sales, reimbursement, and marketing strategies across key market segments to ensure a clear path for growth. Prior to joining InVivo, Ms. Stahl served for 10 years in various roles of increasing responsibility at UnitedHealthcare, most recently as Chief Executive Officer, Community Health Plan of Wisconsin. In that role, she was […]

View Article
InVivo Therapeutics Reports 2016 Second Quarter Financial Results and Business Update

Published: August 4, 2016

CAMBRIDGE, Mass. (August 4, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2016. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “The second quarter was one marked by continued advancements and outreach. In the INSPIRE study, a fourth patient converted from a complete to an incomplete spinal cord injury, putting us one step closer to achieving the Objective Performance Criterion. The InVivo story was disseminated to life science professionals through our article in Life Science Leader; to researchers through our presentations at the 34th Annual Symposium of the National Neurotrauma […]

View Article
InVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE Study

Published: July 18, 2016

CAMBRIDGE, Mass. (July 18, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Ben Taub Hospital in Houston, TX has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Ben Taub Hospital, located in the heart of the Texas Medical Center, is staffed by the Baylor College of Medicine and is the central clinical care facility for the Harris Health System. “I’m thrilled to bring the INSPIRE study to the Ben Taub Hospital,” […]

View Article
InVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study

Published: July 14, 2016

Leading Spinal Cord Researcher Dr. Michael Fehlings and Toronto Western Hospital Join INSPIRE CAMBRIDGE, Mass. (July 14, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received approval from the Toronto Western Hospital’s Research Ethics Board to enroll patients as part of the INSPIRE study. Michael Fehlings, M.D., Ph.D., has been named Principal Investigator at the site. Dr. Fehlings is currently Director of the Spinal Program at Toronto Western Hospital at the University Health Network, Professor in the Department of Surgery, full member  of  the  Institute  of Medical Sciences School of Graduate Studies, a Scholar in the […]

View Article
InVivo Therapeutics Receives Investigational Testing Authorization from Health Canada

Published: July 13, 2016

CAMBRIDGE, Mass. (July 13, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Health Canada has approved the company’s Investigational Testing Authorization application to commence clinical studies in Canada. The authorization will allow the company to enroll Canadian patients into the ongoing INSPIRE study once a Canadian site is open for enrollment. InVivo currently is in late stage conversation with various Canadian Research Ethics Boards and expects to announce its first Canadian site in the coming weeks. “The Canadian scientific and medical community recognizes spinal cord injury as a significant unmet medical need and has been at the forefront of […]

View Article
InVivo Therapeutics Announces Update on the INSPIRE Study and FDA Approval of Expansion of the Study to 20 Evaluable Patients

Published: July 12, 2016

CAMBRIDGE, Mass. (July 12, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today provided an update on the INSPIRE study of the Neuro-Spinal Scaffold™. Patient Enrollments InVivo announced that the 9th and 10th patients have been implanted with the Neuro-Spinal Scaffold in the INSPIRE study. The 9th patient was implanted at Vidant Medical Center, a Level 1 trauma center located in Greenville, North Carolina. The implantation was performed by Vidant Medical Group neurosurgeons Stuart Lee, M.D., the Principal Investigator at the site, and Hilal Kanaan, M.D., approximately 40 hours after the injury occurred. Dr. Lee said, “The implantation procedure went smoothly […]

View Article
InVivo Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Published: July 8, 2016

CAMBRIDGE, Mass. (July 8, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Christopher McNulty, Senior Vice President of Business Development and Investor Relations, is scheduled to present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference to be held July 12-13, 2016 at Le Parker Méridien Hotel in New York City, NY. The company’s presentation will be Tuesday, July 12th at 3:30 PM EDT. “We are pleased to present at Cantor’s healthcare conference two years in a row. This forum affords us the opportunity to connect with both the financial industry and other thought leaders in the space,” Mark Perrin, InVivo’s […]

View Article
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society

Published: June 23, 2016

CAMBRIDGE, Mass. (Jun 23, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Layer, Ph.D., InVivo’s Senior Director of Research, will be giving a poster presentation at the National Neurotrauma Society (NNS) 2016 Symposium to be held June 26-29 in Lexington, KY. The abstract, titled “Biodegradable Neuro-Spinal Scaffold™ Promotes Neuropermissive Tissue Remodeling Following Spinal Contusion Injury in Rats” will be published electronically in the Journal of Neurotrauma immediately prior to the conference. “It’s important to continue to raise awareness about our novel approach to treating spinal cord injuries. We look forward to our participation in the NNS symposium […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.